Related Experiment Video

Updated: Aug 15, 2026

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

[Effects of parathyroid hormone gene polymorphism on cardiovascular mortality]

Yoshihiro Tsujimoto1, Tsutomu Tabata, Takashi Inoue

  • 1Inoue Hospital.

Clinical Calcium
|November 8, 2005
PubMed

Insights

Serum intact parathyroid hormone (PTH) levels and specific gene variations significantly impact cardiovascular mortality in hemodialysis patients, highlighting potential targets for improved patient outcomes.

Area of Science:

  • Nephrology
  • Endocrinology
  • Genetics
  • Cardiovascular Medicine

Context:

  • Secondary hyperparathyroidism is a common complication in uremia, affecting mineral metabolism and contributing to cardiovascular disease.
  • Hemodialysis patients face a high risk of mortality, with cardiovascular complications being a major cause.
  • Understanding the interplay between parathyroid hormone (PTH) and genetic factors in this population is crucial for risk stratification.

Purpose:

  • To investigate the association between serum intact PTH levels, PTH gene polymorphism (BstB I), and mortality in hemodialysis patients.
  • To identify independent predictors of cardiovascular and non-cardiovascular mortality in a cohort of 508 hemodialysis patients over a 3-year period.

Summary:

  • Analysis of 508 hemodialysis patients revealed that elevated serum intact PTH levels and the BstB I genotype were independent predictors of cardiovascular mortality.
  • Diabetes mellitus and low albumin levels were also associated with increased cardiovascular mortality.
  • Age and albumin levels independently predicted non-cardiovascular mortality.

Impact:

  • These findings suggest that serum intact PTH levels and genetic variations in PTH may play a significant role in cardiovascular outcomes for hemodialysis patients.
  • This research provides valuable insights for developing targeted interventions to mitigate cardiovascular risk in patients undergoing hemodialysis.
  • Further research into the mechanisms linking PTH and cardiovascular mortality could lead to novel therapeutic strategies.

More Related Videos

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...